BMJ Case Reports 2012; doi:10.1136/bcr.12.2011.5374
  • Novel treatment (new drug/intervention; established drug/procedure in new situation)

Cetuximab alleviates neuropathic pain despite tumour progression

  1. Marte Grønlie Cameron
  1. Center for Cancer Treatment, Southern Norway Hospital Trust, Kristiansand, Norway
  1. Correspondence to Dr Christian Kersten, christian.kersten{at}


The authors present the case of a 68-year-old male patient with metastatic rectal cancer. A pelvic recurrence resulted in neuropathic pain, radiating down his left leg. The pain was resistant to standard treatments. However, after nearly 3 years of debilitating pain, the patient experienced dramatic relief just hours after an infusion of the antiepidermal growth factor receptor antibody cetuximab. The analgesic effect lasted for 10–12 days and was repeated roughly every 12 days for three and a half years. To test for placebo effect, the patient received (unknown to him) 20% of his usual cetuximab dose and experienced no pain relief. The dramatic analgesic effect was documented in clinical notes, medication lists and in numeric rating scales even while his cancer was in radiological progression. Mitogen-activated protein kinase (MAPK)-signalling is believed to be an important driver of neuropathic pain and therefore, the authors hypothesise a direct inhibition of MAPK-signalling by cetuximab in neuronal or glial cells.


  • CK and MGC contributed equally to this paper.

  • Competing interests We, the authors, have filed a US provisional patent application for the use of EGFR as a clinical target for treatment of neurological disorders. There are no other potential conflicts of interest.

  • Patient consent Obtained.

Register for free content

The full text of all Editor's Choice articles and summaries of every article are free without registration

The full text of Images in ... articles are free to registered users

Only fellows can access the full text of case reports (apart from Editor's Choice) - become a fellow today, or encourage your institution to, so that together we can grow and develop this resource

Don't forget to sign up for content alerts so you keep up to date with all the case reports as they are published, and let us know what you think by commenting on the Editor's blog

Navigate This Article